Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TheraSense Inc.

Division of Abbott Laboratories Inc.
www.therasense.com

Latest From TheraSense Inc.

Can Patents Be Wiped Out Because Of A Litigator's Misconduct? Regeneron Asks Supreme Court

Regeneron challenges Federal Circuit finding that withholding information in discovery constitutes inequitable conduct; district judge orders firm to pay Merus $10.5m in attorneys' fees and costs.

Legal Issues Intellectual Property

Regeneron's Patent Pratfall: First Inequitable Conduct, Now Possible Sanctions

After losing patent infringement suit against Merus involving antibody-producing mouse, Regeneron fights ruling that it withheld material information in prosecuting the patent.

BioPharmaceutical United States

The Wireless Age in Diabetes: Insulet Raises $50 Million

Insulet, developer of a fundamentally new insulin delivery system, just raised $50 million in its fifth venture round. This brings the total it's raised to date to more than $120 million, which sounds like a tremendous sum for a small device company founded just six years ago, but relative to the size of the opportunity it's really not. There are one million diabetic patients who need to inject insulin several times a day to manage their diabetes. For these patients, Insulet has brought insulin pumps into the age of iPods.
Medical Device Business Strategies

J&J Closes the Loop with Animas Acquisition

Johnson & Johnson, whose LifeScan Inc. division is number one in the $6 billion glucose monitoring industry, acquired Animas, which after Medtronic MiniMed, is the number two player in the insulin pump market. J&J gets not only a leading insulin pump business, but also technology that lends itself to the future goals of all diabetes companies; the development of an artificial pancreas, or at least, the ability to automatically deliver insulin in response to automated continuous blood glucose measurements.
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Biosensors
    • Glucose Testing
  • Medical Devices
    • Monitoring Equipment & Devices
  • Therapeutic Areas
  • Metabolic Disorders > Diabetes
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Abbott Laboratories Inc.
  • Senior Management
  • W. Mark Lortz, CEO
    Charles T Liamos, CFO & COO
    Mark Tatro, VP, Fin.
    Shawna Gvazdauskas, VP, Sales
  • Contact Info
  • TheraSense Inc.
    Phone: (510) 749-5400
    1360 South Loop Rd.
    Alameda, CA 94502
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register